Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

99 results

Filters applied: . Clear all
Page 1
Time is myelin: early cortical myelin repair prevents atrophy and clinical progression in multiple sclerosis.
Lazzarotto A, Hamzaoui M, Tonietto M, Dubessy AL, Khalil M, Pirpamer L, Ropele S, Enzinger C, Battaglini M, Stromillo ML, De Stefano N, Filippi M, Rocca MA, Gallo P, Gasperini C, Stankoff B, Bodini B; MAGNIMS Study Group. Lazzarotto A, et al. Brain. 2024 Apr 4;147(4):1331-1343. doi: 10.1093/brain/awae024. Brain. 2024. PMID: 38267729 Free PMC article.
Our findings suggest that early-stage myelin repair compensating for cortical myelin loss has the potential to prevent neuro-axonal loss and its long-term irreversible clinical consequences in people with MS....
Our findings suggest that early-stage myelin repair compensating for cortical myelin loss has the potential to prevent neuro-axonal loss and …
Data-driven modelling of neurodegenerative disease progression: thinking outside the black box.
Young AL, Oxtoby NP, Garbarino S, Fox NC, Barkhof F, Schott JM, Alexander DC. Young AL, et al. Among authors: barkhof f. Nat Rev Neurosci. 2024 Feb;25(2):111-130. doi: 10.1038/s41583-023-00779-6. Epub 2024 Jan 8. Nat Rev Neurosci. 2024. PMID: 38191721 Review.
Data-driven disease progression models are an emerging set of computational tools that reconstruct disease timelines for long-term chronic diseases, providing unique insights into disease processes and their underlying mechanisms. Such methods combine a priori human knowle …
Data-driven disease progression models are an emerging set of computational tools that reconstruct disease timelines for long-term ch …
Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension.
Kappos L, Traboulsee A, Li DKB, Bar-Or A, Barkhof F, Montalban X, Leppert D, Baldinotti A, Schneble HM, Koendgen H, Sauter A, Wang Q, Hauser SL. Kappos L, et al. Among authors: barkhof f. J Neurol. 2024 Feb;271(2):642-657. doi: 10.1007/s00415-023-11943-4. Epub 2023 Oct 31. J Neurol. 2024. PMID: 37906326 Free PMC article.
Open-label extension (OLE) studies help inform long-term safety and efficacy of disease-modifying therapies in multiple sclerosis (MS). ...This is the longest follow-up of ocrelizumab-treated patients with RRMS, with no new safety signals emerging during an observation per …
Open-label extension (OLE) studies help inform long-term safety and efficacy of disease-modifying therapies in multiple sclerosis (MS …
Genetic influences on disease course and severity, 30 years after a clinically isolated syndrome.
Sahi N, Haider L, Chung K, Prados Carrasco F, Kanber B, Samson R, Thompson AJ, Gandini Wheeler-Kingshott CAM, Trip SA, Brownlee W, Ciccarelli O, Barkhof F, Tur C, Houlden H, Chard D. Sahi N, et al. Among authors: barkhof f. Brain Commun. 2023 Oct 4;5(5):fcad255. doi: 10.1093/braincomms/fcad255. eCollection 2023. Brain Commun. 2023. PMID: 37841069 Free PMC article.
In this retrospective study, we explore genetic influences on long-term disease course and severity; in a unique cohort of clinically isolated syndrome patients with homogenous 30-year disease duration, deep clinical phenotyping and advanced MRI metrics. ...HLA-DRB1*1501 i …
In this retrospective study, we explore genetic influences on long-term disease course and severity; in a unique cohort of clinically …
Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS Study.
Ruggieri S, Prosperini L, Al-Araji S, Annovazzi PO, Bisecco A, Ciccarelli O, De Stefano N, Filippi M, Fleischer V, Evangelou N, Enzinger C, Gallo A, Garjani A, Groppa S, Haggiag S, Khalil M, Lucchini M, Mirabella M, Montalban X, Pozzilli C, Preziosa P, Río J, Rocca MA, Rovira A, Stromillo ML, Zaffaroni M, Tortorella C, Gasperini C; MAGNIMS Study Group. Ruggieri S, et al. J Neurol Neurosurg Psychiatry. 2024 Jan 11;95(2):142-150. doi: 10.1136/jnnp-2023-331920. J Neurol Neurosurg Psychiatry. 2024. PMID: 37775266
CONCLUSIONS: Early relapses and substantial MRI activity in the first year of treatment are associated with worse short-term outcomes in patients treated with some of the oral DMTs....
CONCLUSIONS: Early relapses and substantial MRI activity in the first year of treatment are associated with worse short-term outcomes …
The relation of sarcopenia and disability in multiple sclerosis.
Haider L, Chung KK, Mangesius S, Furtner J, Ciccarelli O, Chard DT, Barkhof F. Haider L, et al. Among authors: barkhof f. Mult Scler Relat Disord. 2023 Sep;77:104855. doi: 10.1016/j.msard.2023.104855. Epub 2023 Jul 3. Mult Scler Relat Disord. 2023. PMID: 37442077 Free article.
Cardiovascular risk factors in secondary progressive multiple sclerosis: A cross-sectional analysis from the MS-STAT2 randomized controlled trial.
Williams T, John N, Calvi A, Bianchi A, De Angelis F, Doshi A, Wright S, Shatila M, Yiannakas MC, Chowdhury F, Stutters J, Ricciardi A, Prados F, MacManus D, Braisher M, Blackstone J, Ciccarelli O, Gandini Wheeler-Kingshott CAM, Barkhof F, Chataway J; UCL MS-STAT2 investigators. Williams T, et al. Among authors: barkhof f. Eur J Neurol. 2023 Sep;30(9):2769-2780. doi: 10.1111/ene.15924. Epub 2023 Jun 23. Eur J Neurol. 2023. PMID: 37318885 Clinical Trial.
Association between age and inflammatory disease activity on magnetic resonance imaging in relapse onset multiple sclerosis during long-term follow-up.
Coerver E, Janssens S, Ahmed A, Wessels M, van Kempen Z, Jasperse B, Barkhof F, Koch M, Mostert J, Uitdehaag B, Killestein J, Strijbis E. Coerver E, et al. Among authors: barkhof f. Eur J Neurol. 2023 Aug;30(8):2385-2392. doi: 10.1111/ene.15862. Epub 2023 May 26. Eur J Neurol. 2023. PMID: 37170817
Here, we describe the relation of age and magnetic resonance imaging (MRI) measures of inflammatory disease activity during long-term follow-up in a large real-world cohort of people with relapse onset MS. ...CONCLUSIONS: Greater age is associated with a lower risk of infl …
Here, we describe the relation of age and magnetic resonance imaging (MRI) measures of inflammatory disease activity during long-term …
Plasma biomarkers predict amyloid pathology in cognitively normal monozygotic twins after 10 years.
den Braber A, Verberk IMW, Tomassen J, den Dulk B, Stoops E, Dage JL, Collij LE, Barkhof F, Willemsen G, Nivard MG, van Berckel BNM, Scheltens P, Visser PJ, de Geus EJC, Teunissen CE. den Braber A, et al. Among authors: barkhof f. Brain Commun. 2023 Feb 4;5(1):fcad024. doi: 10.1093/braincomms/fcad024. eCollection 2023. Brain Commun. 2023. PMID: 36824390 Free PMC article.
Implementation of such biomarkers requires a solid understanding of their long-term dynamics and the contribution of confounding to their association with Alzheimer's disease pathology. ...
Implementation of such biomarkers requires a solid understanding of their long-term dynamics and the contribution of confounding to t …
Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis.
van Lierop ZY, Noteboom S, Steenwijk MD, van Dam M, Toorop AA, van Kempen ZL, Moraal B, Barkhof F, Uitdehaag BM, Schoonheim MM, Teunissen CE, Killestein J. van Lierop ZY, et al. Among authors: barkhof f. Mult Scler. 2022 Dec;28(14):2231-2242. doi: 10.1177/13524585221118676. Epub 2022 Sep 3. Mult Scler. 2022. PMID: 36062492 Free PMC article.
BACKGROUND: Despite highly effective treatment strategies for patients with relapsing-remitting multiple sclerosis (RRMS), long-term neurodegeneration and disease progression are often considerable. Accurate blood-based biomarkers that predict long-term neurodegener …
BACKGROUND: Despite highly effective treatment strategies for patients with relapsing-remitting multiple sclerosis (RRMS), long-term …
99 results